NovaBridge Biosciences

NASDAQ:NBP

Biotechnology

Healthcare
$0.90 -4.78%

-$0.07 today

Market cap
$104.10M
Beta
1.48
P/E (TTM)
-25.5
EPS (TTM)
-$0.40
52W Low $1.46High $6.79

Volume 0.87M

Average 0.90M

NBP Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

NovaBridge BiosciencesNASDAQ: NBP

Other Non-Cash Items · Q4 FY2025 · quarter ended Dec 2025

Other non-cash items declines year over year

Q4 FY2025 other non-cash items of $43.82M fell 20.1% year over year, ahead of the -67.1% change in trailing-twelve-month other non-cash items. Sequentially, it rose 260673.6% from the prior quarter. Over 3 fiscal years it compounded at -53.3% a year.

Context

  • Other non-cash items increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -20.1% holds above the trailing-twelve-month pace of -67.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$43.82M+260673.6% QoQ
Last fiscal yearDec 2025
$43.84M+642.4% YoY
LTMSep 2025
$86.65M-67.1% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.1%——
1 year+642.4%——
3-year CAGR-53.3%——
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

Mixed currencies · from the cash flow

Latest · FY2025
43.84M USD
Year-over-year change
—

Other Non-Cash Items vs competitors

How NBP compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -67.1% is the 8th highest of 10, against a peer median of +90.8%.
  • Over three fiscal years its annual growth of -53.3% compares with a peer median of +29.5%.
NBP Competitors
Other Non-Cash Items for NBP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NBPNovaBridge BiosciencesLTM Sep 2025CN¥86.65M CNY-67.1%-53.3%—
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$12.42M USD-60.9%+71.5%—
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$5.66M USD+90.8%——
GALTGalectin Therapeutics Inc.LTM Mar 2026$3.44M USD+1892.2%——
ALTAltimmune, Inc.LTM Mar 2026$2.48M USD+254.0%+43.3%6886.1%
DSGNDesign Therapeutics, Inc.LTM Mar 2026$2.26M USD-59.1%——
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$2.01M USD—-33.1%—
ANNXAnnexon, Inc.LTM Mar 2026$1.21M USD-85.6%——
AURAAura Biosciences, Inc.LTM Mar 2026$252K USD+111.8%——
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$144.11K USD+112.0%+15.7%—
ENGNenGene Holdings Inc.LTM Apr 2026$7K USD-99.4%——
Peer median (excluding NBP) —+90.8%+29.5%6886.1%

Competitors are the stored peer set for NBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CNY
FY2022
Dec 2022 · CNY
FY2023
Dec 2023 · CNY
FY2024
Dec 2024 · CNY
FY2025
Dec 2025 · USD
Net Income(2.33B)(2.51B)(208.18M)(362.72M)(88.34M)
Depreciation & Amortization34.14M63.82M1.06M7.14M856K
Deferred Income Tax00000
Stock-Based Compensation608.61M357.15M10.26M(14.23M)5.97M
Change in Working Capital394.52M552.06M(37.2M)(20.52M)17.07M
Accounts Receivables97.42M33.08M000
Inventory(27.24M)27.24M000
Accounts Payables107.85M0000
Other Working Capital216.49M491.75M(37.2M)(20.52M)17.07M
Other Non-Cash Items321.18M431.48M161.2M5.9M43.84M
Operating Cash Flow(973.09M)(1.1B)(72.85M)(384.42M)(20.6M)
Capital Expenditures(29.93M)(45.83M)(164.35K)(350.34K)(7K)
Acquisitions (Net)(6M)0000
Purchases of Investments(10.17B)(7.41B)0(1.79B)(49.96M)
Sales of Investments9.48B7.91B0801.66M154.89M
Other Investing Activities026K(107.47M)452.53K47K
Investing Cash Flow(727.21M)458.38M(107.63M)(992.42M)104.97M
Debt Repayment02.75M000
Common Stock Issued000061.91M
Common Stock Repurchased0(3.08M)(8.66M)(2.45M)0
Dividends Paid00000
Other Financing Activities593.92M60.86M407.88K0(4.19M)
Financing Cash Flow593.92M42.36M(8.25M)(2.44M)57.73M
Effect of Forex Changes(128.77M)389.2M36.89M(327.04M)276K
Net Change in Cash(1.24B)(212.86M)(151.58M)(1.71B)142.37M
Free Cash Flow(1B)(1.15B)(73.02M)(384.77M)(20.6M)

NovaBridge Biosciences

NASDAQ:NBP

Intrinsic Alpha fair value

Locked

Current Price

$0.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.